Earnings Call Insights: Gilead Sciences, Inc. (GILD) Q4 2025 Management View Daniel O'Day, Chairman & CEO, highlighted "another very strong set of results for Gilead, closing out a remarkable year for the company with clinical, commercial and operational achievements that set the stage for a very promising 2026." He stated the HIV business grew 6% year-over-year, with Biktarvy up 7% and the HIV pr...
Earnings Call Insights: Gilead Sciences, Inc. (GILD) Q4 2025 Management View Daniel O'Day, Chairman & CEO, highlighted "another very strong set of results for Gilead, closing out a remarkable year for the company with clinical, commercial and operational achievements that set the stage for a very promising 2026." He stated the HIV business grew 6% year-over-year, with Biktarvy up 7% and the HIV prevention portfolio up 47%. He noted, "Yeztugo, our twice yearly HIV prevention injectable has already exceeded our coverage goals and is rapidly gaining market share in addition to expanding the reach of HIV prevention to new users." O'Day emphasized up to 10 ongoing and potential new launches through 2027 and called the current clinical pipeline "the strongest pipeline in our almost 40-year history." He said, "With many of the policy-related uncertainties behind us and no major product LOEs until 2036, Gilead is entering 2026 in a position of strength." Andrew Dickinson, Chief Financial Officer, stated, "full year 2025 total product sales of $28.9 billion were up 1% from 2024 and above our $28.4 billion to $28.7 billion guidance range driven by demand-led HIV sales growth that more than offset the $1.1 billion headwind related to Part D redesign and $900 million lower Veklury revenue." Outlook The company expects 2026 total product sales between $29.6 billion and $30 billion. Dickinson said, "We expect base business sales between $29 million and $29.4 billion growth of 4% to 5% compared to 2025." HIV sales, including both treatment and prevention, are projected to grow approximately 6% in 2026. Full year 2026 Yeztugo revenue is expected to reach approximately $800 million compared to $150 million in 2025. Management noted, "absent these headwinds, our HIV business is expected to grow 8% in 2026." The company expects cell therapy revenues to decline approximately 10% in 2026 compared to 2025. Non-GAAP diluted EPS is guided to a range of $8.45 and $8.85 per share for 2026. F...
(RTTNews) - Morguard North American Residential REIT (MRG_UN.TO) announced earnings for its fourth quarter that Dropped from the same period last year The company's earnings totaled $30.69 million. This compares with $42.88 million last year. The company's revenue for the period rose 0.3% to $88.17 million from $87.89 million last year. Morguard North American Residential REIT earnings at glance (...
(RTTNews) - Morguard North American Residential REIT (MRG_UN.TO) announced earnings for its fourth quarter that Dropped from the same period last year The company's earnings totaled $30.69 million. This compares with $42.88 million last year. The company's revenue for the period rose 0.3% to $88.17 million from $87.89 million last year. Morguard North American Residential REIT earnings at glance (GAAP): -Earnings: $30.69 Mln. vs. $42.88 Mln. last year. -Revenue: $88.17 Mln vs. $87.89 Mln last year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The sell-off might be overdone, as the downturn that drove the panic will likely be temporary. Shares of Upwork (UPWK 19.08%) sank on Tuesday after the freelancer marketplace reported a decline in active clients. By the close of trading, Upwork's stock price was down more than 19%. Navigating AI trends Upwork's fourth-quarter revenue rose 4% year over year to $198.4 million. The company's gross se...
The sell-off might be overdone, as the downturn that drove the panic will likely be temporary. Shares of Upwork (UPWK 19.08%) sank on Tuesday after the freelancer marketplace reported a decline in active clients. By the close of trading, Upwork's stock price was down more than 19%. Navigating AI trends Upwork's fourth-quarter revenue rose 4% year over year to $198.4 million. The company's gross services volume (GSV) -- the total dollar value of all transactions facilitated by its platform -- increased 3% to $1 billion. Upwork is making inroads with small and midsize businesses. GSV from its Upwork Business Plus offering for SMBs increased 24% sequentially. The work marketplace is also investing aggressively in artificial intelligence (AI). AI-powered search recommendations helped boost GSV by over $100 million in 2025. Moreover, annualized GSV from AI-related work climbed more than 50% to over $300 million in the fourth quarter. Expand NASDAQ : UPWK Upwork Today's Change ( -19.08 %) $ -3.58 Current Price $ 15.21 Key Data Points Market Cap $2.5B Day's Range $ 14.82 - $ 16.91 52wk Range $ 11.13 - $ 22.84 Volume 19M Avg Vol 3.5M Gross Margin 77.75 % Still, active clients on Upwork's platform fell 6% to 785,000. This understandably concerning decline likely spooked investors. However, during a conference call with analysts, chief financial officer Erica Gessert noted that Upwork's churn rate improved throughout 2025 -- and the company expects to report active client growth in the first quarter of 2026. Growth is set to accelerate In turn, Upwork's 2026 guidance includes: Revenue of $835 million to $850 million, compared to $787.8 million in 2025 Adjusted earnings per share of $1.43 to $1.48, compared to $1.41 "Our diversified growth path across AI, SMB, and enterprise gives us confidence in our guidance of 4% to 6% GSV growth and 6% to 8% revenue growth for the year," Gessert said.
In this article .DJI .IXIC .AXJO .HSI .N225 .SPX Follow your favorite stocks CREATE FREE ACCOUNT 19 November 2025, China, Shanghai: Boats sail past downtown Shanghai on the Huangpu River. The tallest building on the skyline is the Shanghai Tower (rear). Bernd von Jutrczenka | Picture Alliance | Getty Images Asia-Pacific markets traded mostly higher Wednesday, continuing their rally despite AI fear...
In this article .DJI .IXIC .AXJO .HSI .N225 .SPX Follow your favorite stocks CREATE FREE ACCOUNT 19 November 2025, China, Shanghai: Boats sail past downtown Shanghai on the Huangpu River. The tallest building on the skyline is the Shanghai Tower (rear). Bernd von Jutrczenka | Picture Alliance | Getty Images Asia-Pacific markets traded mostly higher Wednesday, continuing their rally despite AI fears and weak economic data spooking U.S. investors. The U.S. December retail sales report showed that consumer spending was flat , missing the 0.4% monthly gain that economists polled by Dow Jones were expecting. In Asia, investors are assessing the latest data coming out from China. The country's consumer price index rose 0.2% in January from a year earlier, China's National Bureau of Statistics data showed Wednesday. That's below economists' forecast of 0.4% increase in a Reuters poll, a sign of continued deflationary pressure in the absence of stronger stimulus. Australia's S&P/ASX 200 was up 1.43%. South Korea's Kospi rose 0.6%, on pace for a third day of gains, while the small-cap Kosdaq was 0.55% higher. Hong Kong's Hang Seng Index added 0.13%, while the mainland CSI 300 lost 0.26%. Japan's markets are closed for a public holiday. Overnight in the U.S., the S&P 500 lost 0.33%, while the Nasdaq Composite slipped 0.59% as AI fears took hold on Wall Street. However, the Dow Jones Industrial Average rose 0.1% to post a closing record of 50,188.14. The index had scored its third consecutive intraday record earlier in the day, a move that comes after it surpassed the 50,000 level for the first time ever last week. — CNBC's Sean Conlon and Sarah Min contributed to this report.